• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Treatment in Early Relapse Multiple Myeloma: Takeaways from EHA 2024

Opinion
Video

Dr. Mikhael discusses treatment in early relapse of multiple myeloma.

Video content above is prompted by the following question:

  • Please discuss recent updates presented at EHA 2024 in early-relapse multiple myeloma from CARTITUDE-4, KARMMA-2, DREAMM-7, and DREAMM-8.
Related Videos
Paula Rodríguez-Otero, MD, PhD
Peter Voorhees, MD, Atrium Health Levine Cancer Institute
Hearn Jay Cho, MD, PhD
Marc S. Raab, MD, PhD, University Hospital Heidelberg
Paula Rodríguez-Otero, MD, PhD
Kelley L. Julian, PharmD, BCOP
Marc S. Raab, MD, PhD, University Hospital Heidelberg
Paula Rodríguez-Otero, MD, PhD, Cancer Center Clínica Universidad de Navarra
Related Content
Top 5 MM Content of 2025

The Top 5 Most-Read Multiple Myeloma Content of 2025

December 29th 2025
Article

These are the most popular multiple myeloma articles from 2025.

Read More

ICYMI: Highlights From EHA 2025

ICYMI: Highlights From EHA 2025

December 26th 2025
Article

Highlights from EHA 2025 included use of bispecific antibodies in more settings and novel approaches for improving outcomes in hard-to-treat patients.

Read More

Top 5 Most-Read Evidence-Based Oncology™ Articles in 2025

Top 5 Most-Read Evidence-Based Oncology™ Articles in 2025

December 22nd 2025
Article

Advances in radiopharmaceuticals, precision medicine, and the importance of diversity in clinical trials for multiple myeloma and cancer care were among the most popular articles with readers in 2025.

Read More

ICYMI: Highlights From AMCP Nexus 2025

ICYMI: Highlights From AMCP Nexus 2025

December 11th 2025
Article

AMCP Nexus 2025 explored innovative health care policies, oncology advancements, and the impact of new regulations on patient access and treatment outcomes.

Read More

Multiple myeloma | Image Credit: © angellodeco-stock.adobe.com

BMI in CAR T: Overweight Status Predicts Worse MM Outcomes

November 29th 2025
Article

A study reveals a U-shaped relationship between BMI and CAR T-cell therapy outcomes in multiple myeloma (MM), highlighting the impact of overweight status on efficacy.

Read More

FDA approval | Image Credit: © muh-stock.adobe.com

FDA Approves Daratumumab and Hyaluronidase-fihj for High-Risk MM

November 6th 2025
Article

The FDA approved daratumumab and hyaluronidase-fihj (Darzalex Faspro), offering a new treatment for high-risk smoldering multiple myeloma.

Read More

© 2026 MJH Life Sciences
AJMC®
All rights reserved.